Palatin Technologies (PTN)
(Delayed Data from AMEX)
$2.11 USD
+0.06 (2.93%)
Updated May 3, 2024 04:00 PM ET
After-Market: $2.09 -0.02 (-0.95%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 121 - 140 ( 194 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q15 Results; Growing Visibility on BMT and Cardio Programs
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q15 Results; Phase III Rolling and Awaiting Pipeline Developments
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Phase III Gets Going; Expect Success; Tweaking Target to $4
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q15 Results; U.S. Phase III BMT Study To Begin Shortly
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FY14 Results; U.S. Pivotal Study in BMT Expected to Begin Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Spread the Word, EU Partner On Board; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Novartis Shines Light on PL-3994 and Natriuretic Peptides; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Novartis Data Important for PTN''s Potential Differentiation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Not the Release We Wanted, But It Was Still Okay; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J